Aptevo Therapeutics (APVO) News Today $1.98 +0.57 (+40.43%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$1.84 -0.14 (-7.07%) As of 07:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APVO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Aptevo Therapeutics Stock Rallies On 100% Remission Rate In Acute Myeloid Leukemia Trial CohortSeptember 16 at 4:39 PM | msn.comAptevo Therapeutics shares spike on promising trial results for leukemia therapySeptember 16 at 12:21 PM | proactiveinvestors.comAptevo Therapeutics stock soars after 100% remission rate in AML trialSeptember 16 at 11:39 AM | za.investing.comAptevo Therapeutics Shares Soar Following 100% Remission Rate in AML TrialSeptember 16 at 11:39 AM | msn.comAptevo Therapeutics Inc. (NASDAQ:APVO) Sees Significant Increase in Short InterestSeptember 14, 2025 | americanbankingnews.comAptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest UpdateSeptember 10, 2025 | americanbankingnews.comAptevo Therapeutics Expands Anti-Cancer Pipeline with PatentsSeptember 5, 2025 | msn.comAptevo Therapeutics expands anti-cancer pipeline with APVO452, APVO451September 5, 2025 | msn.comForm 13G Aptevo Therapeutics Inc. For: 14 AugustAugust 14, 2025 | investing.comAptevo Therapeutics highlights APVO442 preclinical candidate for prostate cancerAugust 13, 2025 | msn.comAptevo Reports 85% Remission in Q2August 12, 2025 | theglobeandmail.comAptevo Meets Nasdaq $2.5M Equity RequirementJuly 16, 2025 | msn.comAPVO Aptevo Therapeutics Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comAPVO - Aptevo Therapeutics Inc Sustainability - MorningstarJuly 2, 2025 | morningstar.comMAptevo Therapeutics Regains Nasdaq Compliance with Equity RaiseJuly 1, 2025 | tipranks.comAptevo Therapeutics Inc. Research & Ratings | APVO | Barron'sJune 24, 2025 | barrons.comAptevo Therapeutics closes $8 million registered direct offeringJune 21, 2025 | investing.comAptevo announces addition of preclinical candidate APVO455 to portfolioJune 21, 2025 | finance.yahoo.comAptevo Therapeutics: Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell EngagersJune 20, 2025 | finanznachrichten.deSmith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market SessionJune 20, 2025 | benzinga.comAptevo Therapeutics Inc.June 19, 2025 | barrons.comAptevo Therapeutics: Mipletamig Demonstrates Compelling Clinical Activity in Frontline AMLJune 18, 2025 | finanznachrichten.deAptevo Therapeutics stock soars after impressive AML treatment resultsJune 18, 2025 | investing.comAptevo More Than Doubles After Favorable Results in Leukemia StudyJune 18, 2025 | marketwatch.comAptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood CancerJune 18, 2025 | benzinga.comAptevo Therapeutics: Aptevo Participating in the BIO International ConventionJune 13, 2025 | finanznachrichten.deAptevo Therapeutics Approves 1-for-20 Reverse Stock SplitMay 23, 2025 | tipranks.comAptevo Therapeutics announces $2M registered direct offeringApril 23, 2025 | markets.businessinsider.comAptevo Therapeutics prices 1.76M shares at $1.19 in registered direct offeringApril 4, 2025 | markets.businessinsider.comAptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-HighApril 3, 2025 | msn.comAptevo reports two additional AML patients achieve remission in RAINIER trialMarch 21, 2025 | markets.businessinsider.comAptevo Therapeutics advances cancer antibody APVO603 in preclinical phaseMarch 20, 2025 | uk.investing.comAptevo Therapeutics provides overview of APVO603 targeting 4-1BB, OX40March 20, 2025 | markets.businessinsider.comAptevo Therapeutics: RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of TreatmentMarch 20, 2025 | finanznachrichten.deAptevo Therapeutics: Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor ImmunotherapyMarch 18, 2025 | finanznachrichten.deAptevo Therapeutics: Aptevo to Participate in March ConferencesMarch 6, 2025 | finanznachrichten.deRoth MKM Sticks to Its Buy Rating for Aptevo Therapeutics (APVO)February 18, 2025 | markets.businessinsider.comAptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVFebruary 16, 2025 | finanznachrichten.deAptevo Therapeutics reports FY24 EPS ($87.38) vs. ($2,316.83) last yearFebruary 14, 2025 | markets.businessinsider.comAptevo Therapeutics files $100M mixed securities shelfFebruary 14, 2025 | markets.businessinsider.comAPVO stock plunges to 52-week low at $3.62 amid steep annual declineFebruary 13, 2025 | msn.comAptevo Therapeutics Stock Draws Retail Attention After Leukemia Trial Data: Retail Extremely BullishDecember 13, 2024 | msn.comAptevo Therapeutics trading halted, volatility trading pauseDecember 13, 2024 | markets.businessinsider.comAptevo Therapeutics trading resumesDecember 12, 2024 | markets.businessinsider.comAptevo Therapeutics announces additional details about APVO442December 5, 2024 | markets.businessinsider.comAptevo Therapeutics announces additional details about APVO442December 5, 2024 | markets.businessinsider.comAptevo Therapeutics: Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at PresentationNovember 26, 2024 | finanznachrichten.deAptevo Therapeutics highlights potential of portfolio in cancer immunotherapyNovember 23, 2024 | markets.businessinsider.comAptevo Therapeutics: First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor TrialNovember 12, 2024 | finanznachrichten.deAptevo Therapeutics (NASDAQ:APVO) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.com Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APVO Media Mentions By Week APVO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APVO News Sentiment▼0.760.63▲Average Medical News Sentiment APVO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APVO Articles This Week▼61▲APVO Articles Average Week Get the Latest News and Ratings for APVO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Aptevo Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies TLPH News LSTA News IBIO News PRPH News THAR News LSB News BLRX News EDSA News MTVA News NRSN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APVO) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APVO Stock Alerts